SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $604,940 | -20.8% | 21,942 | -13.6% | 0.00% | 0.0% |
| Q2 2023 | $763,795 | -17.7% | 25,409 | -0.8% | 0.00% | 0.0% |
| Q1 2023 | $927,815 | +1.4% | 25,609 | -0.2% | 0.00% | 0.0% |
| Q4 2022 | $915,256 | -12.7% | 25,659 | -17.2% | 0.00% | 0.0% |
| Q3 2022 | $1,048,000 | +12.4% | 30,986 | -3.9% | 0.00% | 0.0% |
| Q2 2022 | $932,000 | -7.6% | 32,232 | +3.2% | 0.00% | 0.0% |
| Q1 2022 | $1,009,000 | +7.3% | 31,230 | -3.3% | 0.00% | 0.0% |
| Q4 2021 | $940,000 | +46.4% | 32,289 | +34.1% | 0.00% | 0.0% |
| Q3 2021 | $642,000 | -5.6% | 24,083 | +9.0% | 0.00% | 0.0% |
| Q2 2021 | $680,000 | +30.8% | 22,099 | +11.2% | 0.00% | 0.0% |
| Q1 2021 | $520,000 | +134.2% | 19,877 | +125.3% | 0.00% | – |
| Q4 2020 | $222,000 | +30.6% | 8,823 | +8.3% | 0.00% | – |
| Q3 2020 | $170,000 | +9.7% | 8,145 | +24.5% | 0.00% | – |
| Q2 2020 | $155,000 | +369.7% | 6,540 | +250.7% | 0.00% | – |
| Q1 2020 | $33,000 | -50.7% | 1,865 | -34.1% | 0.00% | – |
| Q4 2019 | $67,000 | -87.8% | 2,828 | -85.9% | 0.00% | -100.0% |
| Q3 2019 | $551,000 | -82.0% | 20,048 | -78.3% | 0.00% | -66.7% |
| Q2 2019 | $3,063,000 | -39.0% | 92,589 | -35.4% | 0.00% | -40.0% |
| Q1 2019 | $5,024,000 | -20.6% | 143,354 | -24.7% | 0.01% | -28.6% |
| Q4 2018 | $6,326,000 | -39.0% | 190,441 | -7.5% | 0.01% | -30.0% |
| Q3 2018 | $10,365,000 | -17.0% | 205,855 | -1.3% | 0.01% | -16.7% |
| Q2 2018 | $12,481,000 | +29.7% | 208,537 | -0.8% | 0.01% | +33.3% |
| Q1 2018 | $9,624,000 | +13.9% | 210,141 | -0.9% | 0.01% | +12.5% |
| Q4 2017 | $8,448,000 | -6.1% | 211,997 | -5.7% | 0.01% | -11.1% |
| Q3 2017 | $8,995,000 | -16.2% | 224,841 | -9.8% | 0.01% | -25.0% |
| Q2 2017 | $10,739,000 | +44.8% | 249,184 | +5.2% | 0.01% | +50.0% |
| Q1 2017 | $7,417,000 | +12.0% | 236,974 | -9.6% | 0.01% | 0.0% |
| Q4 2016 | $6,622,000 | +7.7% | 262,244 | +5.4% | 0.01% | +14.3% |
| Q3 2016 | $6,151,000 | +1214.3% | 248,802 | +981.9% | 0.01% | +600.0% |
| Q2 2016 | $468,000 | +33.0% | 22,996 | -0.2% | 0.00% | – |
| Q1 2016 | $352,000 | -75.2% | 23,040 | -78.2% | 0.00% | -100.0% |
| Q4 2015 | $1,417,000 | -18.9% | 105,483 | -15.3% | 0.00% | 0.0% |
| Q3 2015 | $1,747,000 | +52.7% | 124,576 | +84.9% | 0.00% | +100.0% |
| Q2 2015 | $1,144,000 | – | 67,386 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |